Discover the latest updates on cardiovascular clinical research, innovative studies, and exciting conference news. Join us on our journey as we explore the latest discoveries and innovations transforming how we understand and treat cardiovascular diseases.
In the rapidly evolving landscape of cardiovascular research, the strategic transition between Contract Research Organizations (CROs) is critical. This excerpt delves into the nuances of CRO transitions, highlighting the importance of meticulous planning, transparent communication, and the agility to adapt to new challenges. Understand the pivotal role that CROs play in advancing therapeutic innovations from concept to clinical reality, and explore the strategies that ensure these transitions strengthen, rather than hinder, the research continuum.
Phase 1 clinical studies are the initial step in drug development, designed to assess the safety and tolerability of a new molecule in humans. Traditionally investigational medicinal products (IMP) were tested in multiple Phase 1 clinical trials that enrolled large numbers of healthy participants before a first patient was randomized.
Insights into best practices and efficiency improvement in clinical trials highlight the importance of thorough site identification and selection in the field of cardiovascular research.
The industry spent over $200 billion globally in 2021 on developing new therapies for treating cardiovascular diseases. However, it’s estimated that more than half of
Maike, 32, and Nadja, 32, work as Clinical Research Associates (CRA) in medical research. They discuss what makes this job unique and why they enjoy
SCIRENT is excited to participate at the TCT Conference from October 23-26, 2023, in San Francisco. The Transcatheter Cardiovascular Therapeutics (TCT) conference, hosted by the
How can we help you? We will get in touch shortly.
